A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: dreadful (1), outrageous (1), awful (3)

Manslaughter by doctors

Description
Auto Generated Title On these pages I discuss the clinical law on which our nursing and medical staff rely when caring
Url
/HealthProfessionals/Clinical-law-updates/Manslaughter-by-doctors.aspx

Enfortumab-Vedotin-Pembrolizumab

Description
Chemotherapy Protocol UROTHELIAL CANCER Enfortumab vedotin-Pembrolizumab (EV-P) Regimen • Urothelial – Enfortumab vedotin - Pembrolizumab Indication • First-line treatment of adult patients
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Enfortumab-Vedotin-Pembrolizumab.pdf

Lynch syndrome - patient information

Description
This leaflet contains information about Lynch syndrome.
Url
/Media/UHS-website-2019/Patientinformation/Genetics/Lynch-syndrome-1431-PIL.pdf

Papers Trust Board - 13 May 2025

Description
Agenda Trust Board – Open Session Date Time Location Chair Apologies In attendance 13/05/2025 9:00 - 13:00 Conference Room
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-13-May-2025.pdf

Blood culture sampling policy April 2022 v8

Description
Blood Culture Sampling Policy for Adult and Paediatric Patients Trust reference Description Version number 8.0 This policy lists indications for
Url
/Media/UHS-website-2019/Docs/Policies/Blood-culture-sampling-policy-April-2022-v8.pdf

Cemiplimab

Description
Chemotherapy Protocol SKIN CANCER Cemiplimab (350mg) Regimen  Skin – Cemiplimab (350mg) Indication  Metastatic or locally advanced cutaneous squamous cell carcinoma in patients
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Cemiplimab.pdf

Annual-report-2018-19

Description
ANNUAL REPORT AND ACCOUNTS 2018/19 incorporating the quality account 2018/19 Presented to Parliament pursuant to Schedule 7, paragraph 25
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2018-19.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with; - proven histological diagnosis of endometrial carcinoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Testing for gene variants in inherited breast, ovarian and prostate cancers - patient information

Description
Information about testing for gene variants in inherited breast, ovarian and prostate cancers.
Url
/Media/UHS-website-2019/Patientinformation/Genetics/Testing-for-gene-variants-in-inherited-breast-ovarian-and-prostate-cancers-1980-PIL.pdf

Durvalumab_14day

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf
31 to 40 of 78
Previous … 2 3 4 5 6 … Next